

13 JUN 2005



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 6/10/05 Signature: *[Signature]*
(Ginny Blundell)

Docket No.: WYTH-P01-001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kuai et al.

Application No.: 10/523328

Confirmation No.: 8048

Filed: February 1, 2005

Art Unit: N/A

For: METHODS AND REAGENTS RELATING
TO INFLAMMATION AND APOPTOSIS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of references BA-BB, CA-CS on the PTO/SB/08 are attached.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WYTH-P01-001.

Dated: June 10, 2005

Respectfully submitted,

By 
Z. Angela Guo

Registration No.: 54,144
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/523328
				Filing Date	February 1, 2005
				First Named Inventor	Jun Kuai
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	WYTH-P01-001
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	5,776,717	07-07-1998	Cao, Z.	
	AB	5,837,514	11-17-1998	Cao, Z.	
	AC	6,294,348-B1	09-25-2001	Goeddel, D.V. and Rothe, M.	
	AD	6,365,366-B1	04-02-2002	Cao, Z.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	01/68908-A2	09-20-2001	Tularik Inc.		
	BB	2004/012673-A2	02-12-2004	Wyeth		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Balkwill, F., et al., "TNF is here to stay!," Immunology Today, 21(10) (October 2000).	
	CB	Baud, V. and Karin, M., "Signal transduction by tumor necrosis factor and its relatives," Trends in Cell Biology, 11(9):372-377 (2001).	
	CC	Bell, S. and Kamm, M.A., "Antibodies to tumour necrosis factor α as treatment for Crohn's disease," The Lancet (Commentary), 355:858-860 (2000).	
	CD	Clark, G.J., et al., "p120 GAP Modulates Ras Activation of Jun Kinases and Transformation," The Journal of Biological Chemistry, 272(3):1677-1681 (1997).	
	CE	Fitzgerald, K.A., et al., "IKK ϵ and TBK1 are essential components of the IRF3 signaling pathway," Nature Immunology, 4(5):491-496 (2003).	
	CF	Friedman, E., "The Role of ras GTPase Activating Protein in Human Tumorigenesis," Pathobiology, 63:348-350 (1995).	
	CG	Galon, J., et al., "TNFRSF1A mutations and autoinflammatory syndromes," Current Opinion in Immunology, 12:479-486 (2000).	
	CH	Gamblin, S.J. and Smerdon, S.J., "GTPase-activating proteins and their complexes," Current Opinion in Structural Biology," 8:195-201 (1998).	
	CI	Heyninck, K. and Beyaert, R., "Crosstalk between NF- κ B-Activating and Apoptosis-Inducing Proteins of the TNF-Receptor Complex," Molecular Cell Biology Research Communications, 4:259-265 (2001).	
	CJ	Idriss, H.T. and Naismith, J.H., "TNF α and the TNF Receptor Superfamily: Structure-Function Relationship(s)," Microscopy Research and Technique, 50:184-195 (2000).	
	CK	Jones, R.E. and Moreland, L.W., "Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis," Rheumatic Diseases (Bulletin), 48(3):1-4 (1999).	
	CL	Kishore, N., et al., "IKK-i and TBI-1 are Enzymatically Distinct from the Homologous Enzyme IKK-2," The Journal of Biological Chemistry, 277(16):13840-13847 (2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/523328
				Filing Date	February 1, 2005
				First Named Inventor	Jun Kuai
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	WYTH-P01-001

	CM	Kuai, J. et al., "NAK Is Recruited to the TNFR1 Complex in a TNF α -dependent Manner and Mediates the Production of RANTES", The Journal of Biological Chemistry, 279(51):53266-53271 (2004)	
	CN	MacEwan, D.J., "TNF receptor subtype signalling: Differences and cellular consequences," Cellular Signalling, 14:477-492 (2002).	
	CO	Mak, T.W. and Yeh, W-C., "Signaling for survival and apoptosis in the immune system," Arthritis Research. 09 May 2002, Vol. 4 (Suppl. 3), S243-S252 (online pages 1-19).	
	CP	McFarlane, S.M., et al., "Differential activation of nuclear factor- κ B by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly," FEBS Letters, 515:119-126 (2002).	
	CQ	Natoli, G., et al., "Apoptotic, Non-apoptotic, and Anti-apoptotic Pathways of Tumor Necrosis Factor Signalling," Biochemical Pharmacology, 56:915-920 (1998).	
	CR	Pomerantz, J.L. and Baltimore, D., "NF κ B activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase," The EMBO Journal, 18(23):6694-6704 (1999).	
	CS	Wen, L-P., et al., "Proteolytic cleavage of Ras GTPase-activating protein during apoptosis," Cell Death and Differentiation, 5:729-734 (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/523328

Attorney Docket No.: WYTH-P01-001

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 6/10/05
Date


Signature

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08a/b (21 References)